We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Digital Diagnostic Platform Uses Electronic Technology for Rapid Disease Detection

By LabMedica International staff writers
Posted on 02 Jun 2025

Traditional diagnostic methods often fall short in providing rapid, accurate detection of infectious diseases, leading to delays in treatment and increased transmission. Now, a groundbreaking digital diagnostics platform aims to revolutionize point-of-care testing with real-time, high-sensitivity results.

The platform, developed by IdentifySensors Biologics (Shaker Heights, OH, USA), utilizes advanced graphene-based sensors integrated into a compact, reusable Bluetooth-enabled device. This technology allows for the detection of multiple pathogens from a single saliva sample without the need for enzymatic amplification or reagents, streamlining the diagnostic process. The system comprises a handheld reader and disposable test cartridges capable of identifying up to three pathogens simultaneously. By targeting conserved genomic regions, the platform ensures high specificity and sensitivity, surpassing traditional PCR tests in detecting viral concentrations as low as 200 copies per milliliter.


Image: An algorithm within the Check4 platform interprets data from the cartridge and sends test results to users by text or email (Photo courtesy of IdentifySensors)
Image: An algorithm within the Check4 platform interprets data from the cartridge and sends test results to users by text or email (Photo courtesy of IdentifySensors)

Preliminary clinical trials have demonstrated approximately 98% accuracy in rapid result delivery from verified COVID-19 samples. Beyond COVID-19, the platform is being developed to detect a broad spectrum of pathogens, including RSV, influenza, norovirus, rotavirus, adenovirus, HIV, hepatitis, chlamydia, gonorrhea, herpes, MRSA, Lyme disease, and tropical diseases like Zika and dengue. Its versatility and rapid turnaround make it a promising tool for both clinical settings and at-home testing, facilitating timely medical interventions and reducing disease spread. IdentifySensors has initiated the FDA review process by submitting a pre-EUA for emergency use authorization of a rapid Ebola test on the company's new Check4 platform.

"This is the new internet of things for diagnostics," said IdentifySensors CEO Greg Hummer. "Current molecular tests are old, slow, expensive and require skilled labor. Our rapid detection platform solves that through electronic circuits that connect instantly to cloud-based algorithms and healthcare software systems."

Related Links:
IdentifySensors Biologics


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Serological Pipet Controller
PIPETBOY GENIUS
New
Hemoglobin Stool Test
CerTest FOB 50 + 200 One Step Combo Card Test
New
Hepatitis A Rapid Test
Anti-HAV IgM Rapid Test Kit

Latest Pathology News

New Cancer Testing Standards to Improve Diagnostic Accuracy for Oncology Labs

New Tools Improve Imaging of Cardiac Tissue and Vessels for Earlier Disease Diagnoses

ML Algorithm Accurately Identifies Cancer-Specific Structural in Long-Read DNA Sequencing Data